Transcription Factors
| CSTコード |
包装 |
希望納入価格(円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #2521S | 100 μL | 57,000 | |
|
p53抗体製品一覧
推奨プロトコール
最適な結果を得るために:Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注:各製品に最適化されたプロトコールをリンクしています。
| | |
-
2521:
-
Flow
Immunofluorescence
Immunoprecipitation
Western Blotting
| 用途(希釈倍率) | |
| ウェスタンブロッティング(1:1,000)、免疫沈降(1:500)、免疫蛍光細胞染色(IF-IC)(1:50)、フローサイトメトリー(1:100) |
| 特異性・感度 | |
| 内在性レベルのSer46 がリン酸化されたp53 タンパク質を検出します。他の部位がリン酸化されたp53 タンパク質とは交差しません。 |
| 使用抗原 | |
| ヒトのp53 タンパク質のSer46 周辺領域(合成リン酸化ペプチド) |
Western Blotting
Western blot analysis of extracts from MCF-7 cells treated with etoposide for the indicated times, using Phospho-p53 (Ser46) Antibody.
IP
Immunoprecipitation of extracts from MCF-7 cells treated with etoposide under nondenaturing conditions, using Phospho-p53 (Ser46) Antibody, followed by Western blot analysis using a monoclonal p53 antibody.
Flow Cytometry
Flow cytometric analysis of HT-29 cells, untreated (blue) or UV-treated (green), using Phospho-p53 (Ser46) Antibody.
IF-IC
Confocal immunofluorescent analysis of MCF-7 cells, untreated (left) or etoposide-treated (right), using Phospho-p53 (Ser46) Antibody (green). Actin filaments have been labeled with DY-554 phalloidin (red).
The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites
in vivo
and by several different protein kinases
in vitro
(2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (5,6). p53 can be phosphorylated by ATM, ATR and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,7). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability and activity (8,9). p53 is phosphorylated at Ser392
in vivo
(10,11) and by CAK
in vitro
(11). Phosphorylation of p53 at Ser392 is increased in human tumors (12) and has been reported to influence the growth suppressor function, DNA binding and transcriptional activation of p53 (10,13,14). p53 is phosphorylated at Ser6 and Ser9 by CK1δ and CK1ε both
in vitro
and
in vivo
(13,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse)
in vivo
to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19).
Homeodomain-interacting protein kinase 2 (HIPK2) Phosphorylates Ser46 off p53 in vitro and in vivo (17,18), and p38 can phosphorylate this site in vitro (19).
-
Levine, A.J. (1997)
Cell
88, 323-331.
-
Meek, D.W. (1994)
Semin. Cancer Biol.
5, 203-210.
-
Milczarek, G.J. et al. (1997)
Life Sci.
60, 1-11.
-
Shieh, S.Y. et al. (1997)
Cell
91, 325-334.
-
Chehab, N.H. et al. (1999)
Proc. Natl. Acad. Sci. USA
96, 13777-13782.
-
Honda, R. et al. (1997)
FEBS Lett.
420, 25-27.
-
Tibbetts, R.S. et al. (1999)
Genes Dev.
13, 152-157.
-
Shieh, S.Y. et al. (1999)
EMBO J.
18, 1815-1823.
-
Hirao, A. et al. (2000)
Science
287, 1824-1827.
-
Hao, M. et al. (1996)
J. Biol. Chem.
271, 29380-29385.
-
Lu, H. et al. (1997)
Mol. Cell. Biol.
17, 5923-5934.
-
Ullrich, S.J. et al. (1993)
Proc. Natl. Acad. Sci. USA
90, 5954-5958.
-
Kohn, K.W. (1999)
Mol. Biol. Cell
10, 2703-2734.
-
Lohrum, M. and Scheidtmann, K.H. (1996)
Oncogene
13, 2527-2539.
-
Knippschild, U. et al. (1997)
Oncogene
15, 1727-1736.
-
Oda, K. et al. (2000)
Cell
102, 849-862.
-
Ito, A. et al. (2001)
EMBO J.
20, 1331-1340.
-
Sakaguchi, K. et al. (1998)
Genes Dev.
12, 2831-2841.
-
Solomon, J.M. et al. (2006)
Mol. Cell. Biol.
26, 28-38.
-
D'Orazi, G. et al. (2002)
Nat. Cell Biol.
4, 11-19.
-
Hofmann, T. G. et al. (2002)
Nat. Cell Biol.
4, 1-10.
-
Bulavin, D. V. et al. (1999)
EMBO J.
18, 6845-6854.